Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israeli Drug That Slowed Diseases in Mice to Start Human Trials
Error: Contact form not found.
by i24 News
Scientists at work in laboratory. Photo: Wikimedia Commons.
i24 News – Molecules designed by Israeli scientists that slowed Alzheimer’s and other degenerative diseases in mice began the approval process to become a drug for humans.
Professor Esther Priel and colleagues at Ben Gurion University of the Negev have been researching the molecules for years, and published peer-reviewed research on their effectiveness in mice, according to the Times of Israel (ToI).
These molecules have shown a delaying effect on the onset and progression of Alzheimer’s and amyotrophic lateral sclerosis (ALS).
Priel and her colleagues formed a company, Neuromagen Pharma, but they didn’t have the funds to start pre-clinical trials needed to prepare for human testing.
An investment from an Israeli funder has allowed the process to move forward.
“This investment will allow us to push this to clinical trials, which was something we couldn’t do until now, as pre-clinical trials for FDA approval cost a lot of money,” Priel told ToI.
She stated that the drug is not expected to be a cure, but rather to “delay the onset and progression of the diseases, and improve the quality of life.”
ALS, also known as Lou Gherig’s disease, affects as many as 30,000 people in the United States, according to Hopkins Medicine. There are currently no drugs available to treat the disease.
